Human Development

Adult preventive care: USPSTF A and B recommendations

Clinical Overview and When to Suspect Prevention Gaps

— Grade A: High certainty of substantial net benefit — offer/provide

— Grade B: High certainty of moderate benefit, or moderate certainty of moderate-to-substantial benefit — offer/provide

— Grade C: Selectively offer based on professional judgment and patient preferences

— Grade D: Discourage use (harms outweigh benefits)

— Grade I: Insufficient evidence — clinician judgment

— Vignette emphasizes age, last screening date, family history, or a normal exam

— Patient presents for "annual visit," "establishing care," or "pre-employment physical"

— Stem ends with "What is the most appropriate screening test?" or "Which intervention has the strongest evidence?"

— Cancer screening (cervical, breast, colorectal, lung, prostate counseling)

— Cardiovascular (BP, statins, aspirin, AAA, tobacco)

— Metabolic (diabetes/prediabetes, obesity, lipids)

— Infectious (HIV, HCV, HBV, syphilis, latent TB in risk groups)

— Behavioral (alcohol, tobacco, unhealthy drug use, intimate partner violence)

— Mental health (depression, anxiety in adults)

Board pearl: If the stem gives you a Grade A or B recommendation and a Grade C alternative, the A/B always wins unless the patient has a specific contraindication or shared decision-making consideration (e.g., PSA, aspirin >60). Memorize age cutoffs — the exam loves "patient is 49" vs "patient is 50."

USPSTF framework: Independent panel grading evidence for clinical preventive services in asymptomatic adults

Why it matters on Step 3: The exam tests when to start, stop, and how often to screen — not whether screening exists. Expect ambulatory vignettes asking the single best next step in a healthy or risk-stratified adult

When to suspect a "prevention question":

ACA coverage linkage: USPSTF A and B recommendations must be covered by most insurers without cost-sharing — frequently embedded in health-systems questions

Core domains tested:

Presentation Patterns and Key History

— Asymptomatic adult presenting for routine care

— Age stated explicitly (often near a screening threshold)

— Risk factors woven into social/family history

— Last screening date may be provided — or conspicuously absent

— Question stem isolates one preventive decision

— Age: Most USPSTF recommendations are age-bounded (e.g., colorectal 45–75, lung CT 50–80, AAA 65–75 men who ever smoked)

— Tobacco use: Pack-years drive lung CA screening, AAA screening, and cessation counseling. 20 pack-years + age 50–80 + current smoker or quit <15 years = annual low-dose CT

— Sexual history: Determines HIV, HCV (now universal 18–79), syphilis, chlamydia/gonorrhea screening

— Family history: First-degree relative with CRC <60 → start colonoscopy at 40 or 10 years before index case (ACG, not strictly USPSTF, but tested)

— Reproductive history: Pregnancy status alters statin, ACE, and imaging decisions

— Substance use: Unhealthy alcohol use screening (Grade B) with AUDIT-C or single-item question

— BMI ≥30 → intensive multicomponent behavioral intervention (Grade B)

— Hypertension or dyslipidemia + overweight → healthy diet/PA counseling (Grade B)

— Sexually active adolescents/adults at increased risk for STIs → behavioral counseling (Grade B)

— Any current symptom (chest pain, weight loss, hematochezia) shifts to diagnostic workup, not screening

— Abnormal prior screening result → diagnostic colonoscopy/biopsy, not repeat screening

Step 3 management: When the vignette says "asymptomatic" and lists an age and a risk factor, your first move is to map the patient onto the USPSTF grid. Don't be distracted by attractive Grade C or I services — pick the highest-evidence intervention not yet performed.

Typical exam vignette structure:

Key history elements to extract:

Behavioral counseling cues:

Red flags the question is NOT about prevention:

Physical Exam Findings (and Vital-Sign-Based Screening)

— Blood pressure (Grade A): Screen adults ≥18. Confirm elevated office readings with out-of-office measurement (ambulatory or home BP monitoring) before diagnosing hypertension — this is heavily tested

— Obesity (Grade B): Calculate BMI at every visit; ≥30 triggers intensive behavioral intervention referral (≥12 sessions/year)

— Abdominal palpation: Not a USPSTF screening modality for AAA — ultrasound is the test; one-time screen in men 65–75 who ever smoked (Grade B); selective in nonsmoking men (Grade C); insufficient in women who never smoked (Grade I)

— Two elevated BP readings on separate occasions, or ABPM/HBPM confirmation, define hypertension

— White coat hypertension: elevated office, normal out-of-office → no antihypertensives, continue lifestyle and repeat monitoring

— Masked hypertension: normal office, elevated out-of-office → treat

Key distinction: Many physical exam maneuvers that feel like prevention (skin survey, carotid auscultation, testicular exam, pelvic exam in asymptomatic women) are Grade I or D by USPSTF. The exam rewards you for not ordering them as screening. The correct screening answer is almost always an evidence-based imaging study, lab, questionnaire, or counseling intervention — not a physical maneuver.

The exam IS the screen for several Grade A/B services:

Vital-sign documentation pearls:

Skin exam: USPSTF says insufficient evidence (Grade I) for routine whole-body skin cancer screening in asymptomatic adults — don't pick "full skin exam" as the screening answer

Visual acuity: Grade I in older adults for screening by primary care — distinguish from comprehensive ophthalmologic exam in diabetics (that's diabetes management, not USPSTF screening)

Oral exam: Grade I for oral cancer screening in asymptomatic adults — refer to dentistry

Auscultation for carotid bruits: Grade D — do NOT screen for asymptomatic carotid stenosis in the general population

Diagnostic Workup — Cancer Screening Recommendations

— Ages 21–29: Cytology every 3 years

— Ages 30–65: Cytology q3y, OR high-risk HPV testing q5y, OR co-testing q5y

— Stop at 65 if adequate prior negative screening and not high risk

— Post-hysterectomy with cervix removed for benign disease: stop screening (Grade D)

— Biennial mammography ages 40–74 (lowered from 50)

— ≥75: insufficient evidence (Grade I)

— BRCA risk assessment in women with personal/family history suggestive of hereditary syndrome (Grade B) — refer for genetic counseling

— Options: colonoscopy q10y, FIT annually, FIT-DNA q1–3y, flexible sigmoidoscopy q5y, CT colonography q5y

— Ages 76–85: selective (Grade C) based on health, prior screening, preference

— Any positive non-colonoscopy test → diagnostic colonoscopy, not repeat stool test

— Annual low-dose CT, ages 50–80, 20 pack-year history, currently smoke or quit within 15 years

— Stop if quit >15 years, develop limiting comorbidity, or unwilling to undergo curative surgery

— Individualized shared decision-making; not routinely offered

— Grade D ≥70

Board pearl: When a vignette gives a 45-year-old with no risk factors, the new answer for colorectal cancer is start screening now — not wait until 50. Similarly, a 42-year-old woman asking about mammography: offer biennial mammography (updated 2024). The exam updates lag guidelines by 12–18 months, so know both the prior and current cutoff, but trust the current USPSTF.

Cervical cancer (Grade A):

Breast cancer (Grade B, updated 2024):

Colorectal cancer (Grade A: 50–75; Grade B: 45–49):

Lung cancer (Grade B):

Prostate cancer (Grade C, 55–69):

Cervical, breast, colorectal, lung = the "big four" cancer A/B screens

Diagnostic Workup — Cardiovascular, Metabolic, and Infectious Screens

— Hypertension (A): All adults ≥18, confirm out-of-office

— Statin for primary prevention (B): Ages 40–75 with ≥1 CVD risk factor AND 10-year ASCVD risk ≥10% — start low/moderate-intensity statin

— Aspirin primary prevention: Ages 40–59 with ≥10% 10-year ASCVD risk → Grade C (individualize). Age ≥60 → Grade D (do not initiate)

— AAA (B): One-time abdominal US, men 65–75 who ever smoked

— Tobacco cessation (A): Ask all adults; offer behavioral + pharmacotherapy

— Prediabetes/T2DM (B): Screen adults 35–70 who are overweight/obese; offer or refer to intensive behavioral intervention if prediabetes detected

— Lipid disorders: Part of ASCVD risk assessment, not a standalone A/B in recent updates

— Obesity (B): BMI ≥30 → intensive behavioral intervention

— HIV (A): One-time screen ages 15–65; pregnant persons; risk-based rescreening

— HCV (B): One-time screen all adults 18–79

— HBV (B): Screen adolescents and adults at increased risk

— Syphilis (A): Asymptomatic nonpregnant adults at increased risk; all pregnant persons (A)

— Chlamydia/gonorrhea (B): Sexually active women ≤24 and older women at increased risk

— Latent TB (B): Adults at increased risk (foreign-born from high-prevalence areas, congregate living)

Step 3 management: A 55-year-old with HTN and LDL 140, ASCVD 10-year risk 12%, no prior CV event → start moderate-intensity statin (Grade B), not aspirin. For a 62-year-old asking about aspirin for primary prevention: do not initiate — Grade D at ≥60.

Cardiovascular:

Metabolic:

Infectious disease:

PrEP for HIV (Grade A): Offer to persons at increased risk of HIV acquisition

Risk Stratification and Behavioral/Mental Health Screening

— Depression (B): All adults, including pregnant and postpartum; use PHQ-2 → PHQ-9

— Anxiety (B, 2023): Adults <65; insufficient evidence ≥65 (Grade I)

— Suicide risk: Grade I in general adult population — screen depression, but routine suicide screening lacks evidence

— Must have systems in place for accurate diagnosis, effective treatment, and appropriate follow-up before screening — tested concept

— Unhealthy alcohol use: Screen with AUDIT-C or single-item; brief behavioral counseling

— Tobacco: Ask, advise, refer; pharmacotherapy + behavioral combined most effective

— Unhealthy drug use (B): Ask adults ≥18 when services for accurate diagnosis, treatment, and care can be offered or referred

— Screen women of reproductive age; provide or refer to ongoing support services

— Folic acid 0.4–0.8 mg daily for all persons planning/capable of pregnancy (Grade A)

— Screen for gestational diabetes at 24 weeks (Grade B)

— Aspirin 81 mg after 12 weeks in those at high preeclampsia risk (Grade B)

— Bacteriuria screening with urine culture 12–16 weeks (Grade B)

— Vitamin D for fall prevention: Grade D — do not recommend

Board pearl: USPSTF screens for depression and anxiety, NOT for dementia (Grade I) or suicide as standalone (Grade I) in general adults. If the stem asks about cognitive screening in an asymptomatic 75-year-old — the answer is no routine screening recommended, address symptoms when reported by patient or family.

Mental health screens (all Grade B unless noted):

Substance use (all Grade B):

Intimate partner violence (Grade B):

Pregnancy-related preventive services (when applicable):

Falls in older adults (Grade B): Exercise interventions in community-dwelling adults ≥65 at increased fall risk

Bone density (Grade B): Women ≥65, or postmenopausal <65 at increased fracture risk (FRAX ≥9.3%)

Pharmacotherapy — Chemoprevention and Vaccines (Grade A/B Drug Recommendations)

— 81 mg daily after 12 weeks gestation in pregnant persons at high risk (prior preeclampsia, chronic HTN, T1/T2DM, renal disease, autoimmune, multifetal gestation)

— Ages 40–59 with ≥10% 10-year ASCVD risk: Grade C (individualize, consider bleeding risk)

— Age ≥60: Grade D (do not initiate)

— Continue if already on for secondary prevention — that's ACC/AHA territory, not USPSTF

— Ages 40–75 with ≥1 risk factor (dyslipidemia, DM, HTN, smoking) AND 10-year ASCVD risk ≥10% → low/moderate intensity statin

— Ages 40–75, risk 7.5–<10%: Grade C

— Age ≥76: Grade I

— 0.4–0.8 mg daily for all persons planning/capable of pregnancy, beginning ≥1 month before conception through first trimester

— Risk-assess women with family/personal history; refer for genetic counseling and possible testing

— Tamoxifen/raloxifene/aromatase inhibitor for breast cancer primary prevention in women at increased risk and low risk of adverse effects (Grade B)

— Persons at increased HIV risk; daily oral PrEP or long-acting injectable cabotegravir

Step 3 management: A 46-year-old smoker, BP 142/88, LDL 150, calculated ASCVD risk 11% → start moderate-intensity statin (e.g., atorvastatin 20 mg) plus tobacco cessation pharmacotherapy. Do NOT add aspirin — Grade C in this age band and bleeding risk often nets out negative; the safer board answer is statin alone unless the stem explicitly asks about aspirin.

Aspirin for preeclampsia prevention (Grade B):

Aspirin for cardiovascular primary prevention:

Statins for CVD primary prevention (Grade B):

Folic acid (Grade A):

BRCA-related cancer risk reduction (Grade B):

PrEP (tenofovir-based) for HIV (Grade A):

Vitamin D, calcium, multivitamins for primary prevention of CVD or cancer: Grade D or I — do not recommend

Implementation — Shared Decision-Making and Counseling Interventions

— Healthy diet & physical activity for CVD prevention in adults with CV risk factors (B)

— Healthful behaviors in adults without CV risk factors: Grade C — individualize

— Skin cancer behavioral counseling for fair-skinned persons ages 6 months–24 years (B); selective 25+ (C)

— Tobacco cessation counseling + pharmacotherapy (A in adults; B in pregnancy — counseling only, pharmacotherapy individualized)

— Sexual transmission of STIs: behavioral counseling for sexually active adolescents and adults at increased risk (B)

— Obesity-related morbidity: intensive multicomponent behavioral intervention for BMI ≥30 (B)

— First-line: varenicline, bupropion SR, nicotine replacement therapy (combine long-acting patch + short-acting gum/lozenge for best efficacy)

— Counseling + pharmacotherapy > either alone

— In pregnancy: behavioral counseling first-line; NRT individualized (insufficient evidence)

— PSA (55–69): Discuss benefits/harms; many false positives, overdiagnosis, biopsy harms

— Lung CT screening: Discuss false positives, incidental findings, radiation, downstream procedures

— Aspirin 40–59: Weigh CV benefit vs GI/intracranial bleed

— BRCA testing: Genetic counseling before testing

Board pearl: When a stem describes a 60-year-old man asking about prostate cancer screening, the correct USPSTF answer is "discuss benefits and harms" — not "order PSA" and not "do not test." Above 70, the answer flips to "do not screen." This is a classic Step 3 distinction between what to do and how to communicate.

Behavioral counseling interventions (Grade B unless noted):

Tobacco cessation pharmacotherapy options:

Shared decision-making domains (frequent stems):

Documentation requirements: Shared decision-making conversations must be documented — patient safety/quality measure tested in systems-based questions

Special Populations — Elderly and Renal/Hepatic Considerations

— Cervical: Stop at 65 with adequate prior negative screening

— Breast mammography: Stop at 75 (Grade I above)

— Colorectal: Selective 76–85 (Grade C); generally stop at 85

— Lung CT: Stop at 80, or earlier if quit >15 years, develops limiting comorbidity, or unwilling/unable to have curative lung surgery

— AAA: One-time screen 65–75 men who smoked; no benefit to rescreening if initial negative

— Prostate: Stop at 70 (Grade D)

— Cancer screening benefit accrues over 7–10 years; if estimated life expectancy <10 years, harms typically outweigh benefits

— Tools: Lee/ePrognosis can be referenced but exam uses clinical judgment cues (advanced dementia, metastatic disease, frailty, hospice)

— Community-dwelling adults ≥65 at increased fall risk → exercise interventions

— Multifactorial interventions: Grade C (selectively offer)

— Vitamin D supplementation to prevent falls: Grade D in community-dwelling adults — do NOT recommend

— Statins: dose adjustment in advanced CKD; avoid in active liver disease (rare absolute contraindication)

— Aspirin: avoid in eGFR <30 with high bleed risk

— Metformin (if prediabetes treated): contraindicated eGFR <30; caution 30–45

— Women ≥65, or postmenopausal <65 with FRAX 10-yr major osteoporotic fracture risk ≥9.3%

— Men: Grade I — insufficient evidence

Step 3 management: An 82-year-old with metastatic cancer and life expectancy <2 years asks about colonoscopy — the correct answer is do not screen; focus on symptom-directed care and quality of life. The exam rewards recognizing when less is more.

Stopping screening — the "deprescribing prevention" concept:

Life-expectancy framing:

Falls prevention (Grade B):

Renal/hepatic adjustments in chemoprevention:

Osteoporosis screening (Grade B):

Special Populations — Pregnancy, Adolescents, and Sexual/Gender Minorities

— Folic acid 0.4–0.8 mg daily preconception–first trimester (A)

— Tobacco cessation behavioral counseling in pregnancy (A)

— Hepatitis B in pregnancy at first prenatal visit (A)

— HIV in pregnancy (A)

— Syphilis in pregnancy (A)

— Asymptomatic bacteriuria, urine culture at 12–16 weeks (B)

— Rh(D) incompatibility screening at first visit (A)

— Gestational diabetes at ≥24 weeks (B)

— Aspirin 81 mg for preeclampsia prevention after 12 weeks in high-risk (B)

— Perinatal depression: counseling interventions for those at increased risk (B); screen for depression (B)

— Breastfeeding support interventions (B)

— Depression ages 12–18 (B); anxiety ages 8–18 (B)

— HIV starting age 15 (A)

— Obesity ages ≥6: refer to comprehensive intensive behavioral interventions (B)

— Tobacco use prevention primary care interventions ages <18 (B)

— Skin cancer counseling ages 6 months–24 (B) for fair-skinned

— Chlamydia and gonorrhea screening if ≤24 or older at increased risk (B)

— Cervical screening starting age 21

— Folic acid if capable of pregnancy

— USPSTF recommendations apply based on anatomy present and risk factors, not gender identity alone

— Cervix present → cervical screening per guideline

— Breast tissue with significant exposure to estrogen → individualized breast screening discussion

Board pearl: For a 28-year-old pregnant patient with chronic hypertension, the highest-evidence preventive intervention to add at 13 weeks is low-dose aspirin 81 mg daily to reduce preeclampsia risk — Grade B with strong outcome data. This is a recurring Step 3 stem.

Pregnancy-specific Grade A/B:

Adolescents:

Sexually active women:

Transgender and gender-diverse patients:

Complications and Adverse Outcomes of Screening

— PSA: detection of indolent prostate cancer leading to biopsy complications (bleeding, infection, sepsis) and treatment harms (incontinence, ED)

— Mammography: false positives lead to biopsy, anxiety; DCIS overdiagnosis

— Lung CT: high false-positive rate (~25% any nodule); biopsy complications include pneumothorax (~15%) and hemorrhage

— Thyroid cancer screening: Grade D — overdiagnosis of indolent papillary cancers

— Colonoscopy: perforation ~1/1000, post-polypectomy bleeding, sedation risk

— Prostate biopsy: sepsis 1–4%, hematuria, hematospermia

— CT-guided lung biopsy: pneumothorax 15–25%, chest tube 5–10%

— Aspirin: GI bleed, intracranial hemorrhage (esp. >60) — the reason USPSTF downgraded primary prevention aspirin

— Statins: myalgia (common), rhabdomyolysis (rare), transaminase elevation, modest diabetes incidence increase

— Tamoxifen for breast cancer prevention: VTE, endometrial cancer, hot flashes

— PrEP: renal dysfunction (TDF/FTC), bone mineral density loss; monitor renal function and STIs q3 months

— Incidental findings on lung CT (adrenal, thyroid, liver lesions) trigger workups

— Each downstream test has its own complications — quantify before screening

Key distinction: USPSTF grades incorporate both benefits AND harms. A test can be effective at detecting disease yet still receive Grade D (e.g., aspirin ≥60, vitamin D for falls, thyroid screening) because harms outweigh benefits. Step 3 questions often present a "high-tech" screening option as a distractor — the correct answer recognizes net harm.

Overdiagnosis and overtreatment:

Procedural complications:

Chemoprevention harms:

Psychological harms: false-positive screening anxiety, labeling effects (e.g., hypertension diagnosis affecting employment/insurance)

Cascade of care risks:

When to Escalate — Referral, Diagnostic Workup, and Specialist Triage

— Positive FIT or stool DNA → colonoscopy (not repeat FIT)

— Abnormal mammogram (BI-RADS 4/5) → diagnostic mammography ± ultrasound, then biopsy

— Suspicious lung nodule on LDCT → Lung-RADS pathway (PET, biopsy, or short-interval CT)

— Elevated PSA → urology referral for repeat PSA, MRI, possible biopsy

— Positive HIV screen → confirmatory antibody differentiation + RNA, link to ID

— Reactive HCV antibody → HCV RNA to confirm active infection

— Abnormal cervical cytology/HPV → colposcopy per ASCCP guidelines

— Family history suggestive of BRCA1/2: ≥2 first/second-degree relatives with breast/ovarian/peritoneal/tubal cancer, male breast cancer, Ashkenazi Jewish ancestry with affected relative

— Lynch syndrome features: CRC <50, multiple Lynch-associated cancers

— PHQ-9 ≥10 → initiate treatment (SSRI ± therapy); PHQ-9 ≥20 or active SI → urgent psychiatric evaluation

— Positive IPV screen → safety planning, social work referral, document carefully

— Calculated ASCVD risk plus discordance with patient values → consider coronary artery calcium score (CAC) as risk modifier — ACC/AHA, not USPSTF

— Resistant hypertension after 3 agents including a diuretic

CCS pearl: On CCS prevention cases, after ordering a screening test, advance the clock and act on the result. Positive FIT → order colonoscopy on the same encounter. Elevated BP → order ambulatory or home BP monitoring, schedule 1-week follow-up. Do not order repeat screening tests as a substitute for diagnostic workup.

Abnormal screening results require diagnostic, not repeat screening:

Genetic counseling referrals (Grade B):

Behavioral health escalation:

Cardiology referral:

Endocrine referral: New prediabetes → DPP-modeled intensive lifestyle intervention; consider metformin if BMI ≥35, age <60, prior GDM

Key Differentials — Conflicting or Overlapping Guidelines

— Breast cancer: USPSTF now 40–74 biennial; ACS recommends annual 45–54, then biennial; ACOG offers annual starting 40. Pick USPSTF on Step 3 unless stem specifies another society

— Cervical cancer: ACS 2020 recommends starting at 25 with primary HPV; USPSTF still starts at 21 with cytology. Default to USPSTF

— Colorectal: USPSTF 45–75 (A 50–75, B 45–49); ACG agrees; ACS aligned at 45

— Prostate: USPSTF Grade C 55–69, D ≥70; AUA offers shared decision-making 55–69 and earlier in high-risk Black men/family history. USPSTF wins on the boards

— Lung: USPSTF 50–80, 20 pack-years; NCCN broader. USPSTF wins

— USPSTF: Grade C 40–59, Grade D ≥60 for primary prevention

— ACC/AHA: similarly conservative — generally do not initiate >70 or with bleed risk

— Secondary prevention (post-MI, stroke, stent): always continue — separate question

— USPSTF: 40–75, ≥1 risk factor, ASCVD ≥10%

— ACC/AHA: 40–75, LDL 70–189, ASCVD ≥7.5% (moderate), ≥20% (high)

— On Step 3, USPSTF threshold (≥10%) is the safer answer unless stem invokes ACC/AHA

— USPSTF: 35–70, overweight/obese

— ADA: ≥35 universal, or younger with risk factors

— Stem-dependent; USPSTF age 35 is the new floor

Board pearl: When two correct-sounding answers exist (start mammogram at 40 vs 50), the USPSTF current recommendation governs the boards. The 2024 update lowered breast screening to 40 — this is now the right answer. Anchor on the most recent USPSTF.

USPSTF vs specialty societies — when they disagree:

Aspirin discordance:

Statin discordance:

Diabetes screening:

Key Differentials — "Looks Like Prevention" but Isn't

— Symptomatic patient → diagnostic workup, NOT screening (a patient with rectal bleeding gets diagnostic colonoscopy, not FIT)

— Surveillance after disease: post-polypectomy colonoscopy, post-treatment cancer follow-up — guided by specialty society, not USPSTF

— Pre-operative testing: routine ECG, CXR, CBC in asymptomatic patients before low-risk surgery → Choosing Wisely: do not order routinely

— Annual physical labs: routine CBC, CMP, TSH, urinalysis in asymptomatic adults → no USPSTF recommendation — do not order reflexively

— Aspirin primary prevention ≥60

— Vitamin D for fall prevention in community-dwelling elderly

— Beta-carotene or vitamin E for CVD/cancer prevention

— Hormone therapy for primary prevention of chronic conditions in postmenopausal women

— Screening for asymptomatic carotid stenosis

— Screening pelvic exam in asymptomatic, non-pregnant women

— Screening for ovarian cancer (CA-125, transvaginal US)

— Screening for pancreatic cancer in asymptomatic adults

— Screening for thyroid cancer

— Cognitive impairment screening in older adults

— Vitamin D screening in adults

— Routine oral cancer screening

— Lipid screening in children

— Screening for atrial fibrillation with ECG in asymptomatic adults

— Glaucoma screening, hearing loss in older adults

Key distinction: If the exam offers "routine CBC/CMP/TSH/UA" as part of an annual physical for a healthy 45-year-old, it is wrong. The correct preventive package is task-specific: BP, BMI, evidence-based cancer screening, behavioral counseling, immunizations, and chemoprevention — not a shotgun lab panel.

Diagnostic vs screening tests (commonly confused):

Tests USPSTF says NOT to do (Grade D):

Tests USPSTF says insufficient evidence (Grade I) — do not pick as the screening answer:

Secondary Prevention and Long-Term Plan — Tying USPSTF to Chronic Disease

— Post-MI/stroke: aspirin + statin + BP control + smoking cessation — automatic, not USPSTF

— Diabetes: ASCVD risk reduction with high-intensity statin if 40–75 with DM; SGLT2/GLP-1 for kidney/CV benefit; A1c target individualized

— CKD: SGLT2 inhibitor for albuminuria, ACEi/ARB, statin if age ≥50

— Colorectal: colonoscopy 1 year post-resection, then per pathology

— Breast: annual mammography, clinical exam q6–12 months

— Prostate: PSA per urology

— Skin: dermatology follow-up

— Influenza annually

— Tdap once, then Td/Tdap q10y

— RSV ≥75 (and 60–74 with risk factors)

— Pneumococcal ≥65 (PCV20 or PCV15+PPSV23)

— Shingles (RZV) ≥50, two doses

— HPV through age 26 (shared decision 27–45)

— COVID-19 per current ACIP

— HepB all adults 19–59

— Statin: lipid panel 4–12 weeks after initiation, then annually; LFTs only if symptomatic

— Aspirin: GI symptoms, bleeding signs

— PrEP: HIV test, renal function, STIs q3 months

Step 3 management: A 45-year-old with new T2DM and ASCVD risk 8% — they cross from USPSTF "screen for diabetes" into ADA/ACC-AHA territory. Initiate moderate-to-high intensity statin regardless of LDL (DM 40–75 is a statin-benefit group), metformin, lifestyle intervention, and ACEi if albuminuric. Build the longitudinal plan from this single ambulatory visit.

Once disease is diagnosed, the USPSTF lens shifts to secondary prevention (governed by ACC/AHA, ADA, etc.):

Cancer survivor surveillance (specialty-driven, but tested):

Immunizations layered onto preventive care (ACIP, often packaged with USPSTF stems):

Chemoprevention longitudinal monitoring:

Follow-Up, Monitoring Parameters, and Counseling Cadence

— Healthy adults: annual or biennial visit; BP at least every 2 years if <120/80, annually if 120–129/<80

— BMI every visit

— Tobacco/alcohol/drug screen annually

— Depression annually with appropriate follow-up systems

— Cervical cytology q3y (21–29); cytology q3y or HPV-based q5y (30–65)

— Mammography q2y (40–74)

— Colonoscopy q10y; FIT annually; FIT-DNA q1–3y; flex sig q5y; CT colonography q5y

— Low-dose lung CT annually (50–80, eligible smokers)

— AAA US once (65–75 male smokers)

— DEXA ≥65 women (interval guided by T-score; q2y if osteopenic, q15y if normal)

— HIV at least once; rescreen risk-based

— HCV at least once for all adults 18–79

— Statin: ALT baseline (not routine repeat unless symptomatic), lipid 4–12 weeks then annual

— Aspirin pregnancy: continue to 36 weeks

— Folic acid: through first trimester at minimum

— PrEP: HIV q3 months, creatinine q6 months, STI q3–6 months

— Obesity intensive intervention: ≥12 sessions in first year

— Tobacco: combine behavioral + pharmacotherapy; follow-up at 1, 4, 12 weeks

— Alcohol brief intervention: 10–15 min, follow-up 1–3 months

— Document shared decision-making for PSA, lung CT, aspirin 40–59

— Quality measures (HEDIS, MIPS) track A1c, BP, breast/cervical/colorectal screening rates

CCS pearl: When advancing the clock on a prevention case, schedule the next preventive action by name and date: "Mammogram in 24 months," "FIT in 12 months," "BP recheck in 1 week." Vague "follow up" loses points; specific cadence reflects real ambulatory practice.

Routine adult preventive visit cadence:

Screening test intervals (memorize):

Chemoprevention monitoring:

Behavioral counseling intensity:

Documentation and registries:

Ethical, Legal, and Patient Safety Considerations

— PSA, lung CT, aspirin 40–59, BRCA testing: require documented shared decision-making discussion of benefits, harms, alternatives

— Patient values and preferences must be elicited — not just clinician preference

— A patient who declines screening after informed discussion: document refusal; revisit annually

— Grade A and B USPSTF services must be covered by most private insurers and Medicaid expansion plans without cost-sharing

— Tested as a systems-based question: a patient skipping screening due to cost should be educated that A/B services are covered

— Intimate partner violence: state laws vary; mandatory reporting is NOT required in most states for competent adults — respect autonomy and safety planning. Child abuse and elder abuse: mandatory reporting when suspected

— Reportable infectious diseases: HIV, syphilis, gonorrhea, chlamydia, TB, HBV, HCV — report to local health department per state law

— Suicide risk: duty to protect; involve psychiatric services, consider involuntary hold if imminent danger

— GINA prohibits health insurance and employment discrimination based on genetic information (does NOT cover life or disability insurance)

— BRCA results affect family members — discuss cascade testing implications before testing

— After hospital discharge, screening gaps widen — incorporate medication reconciliation and preventive care reconciliation

— Hand-offs between PCPs: ensure cancer screening history transfers (last colonoscopy, mammogram dates)

— Each incidental finding carries downstream risk — counsel before, not after, screening

— Avoid screening when life expectancy <10 years for cancer screens

Step 3 management: A 34-year-old woman discloses IPV during a routine screen. The correct response: acknowledge, assess immediate safety, provide resources (national hotline, local shelter), offer warm handoff to social work, document carefully. Do NOT mandatorily report unless state-specific or involving a child/elder; do NOT contact the partner.

Informed consent and shared decision-making:

ACA mandate and access:

Mandatory reporting and disclosure:

Genetic testing ethics:

Transition-of-care risks:

Patient safety in screening cascades:

High-Yield Associations and Rapid-Fire Clinical Facts

— Cervical 21–65

— Breast 40–74

— Colorectal 45–75 (A 50–75, B 45–49)

— Lung 50–80

— AAA 65–75 (male, ever smoked)

— Prostate 55–69 (shared decision)

— Diabetes 35–70 (overweight/obese)

— HIV 15–65

— HCV 18–79

— Statin 40–75

— Aspirin (primary prevention): Grade C 40–59, Grade D ≥60

— Osteoporosis: women ≥65

— AAA, HIV (baseline), HCV (baseline)

— 1 ppd × 20 years = 20 pack-years (meets lung CT threshold)

— 2 ppd × 10 years = 20 pack-years

— ≥10% + age 40–75 + ≥1 risk factor → statin (USPSTF B)

— 7.5–10% → consider (C)

— Aspirin 40–59: ≥10% with low bleed risk individualize (C)

— Vitamin D for fall prevention

— Beta-carotene, vitamin E for CVD/cancer

— Aspirin ≥60 for primary prevention

— Screening pelvic exam in asymptomatic

— Asymptomatic carotid stenosis screening

— Ovarian, thyroid, pancreatic cancer screening

— Postmenopausal hormone therapy for chronic disease prevention

Board pearl: When you see a 65-year-old male former smoker, immediately layer: AAA US (once), lung CT if eligible (pack-years + recency), colonoscopy through 75, BP, statin if ASCVD ≥10%, RZV, pneumococcal, influenza, RSV at 75. Build the panel in your head — the exam will pick one to ask.

Age cutoffs to memorize (extremely high-yield):

"Once" screens:

Pack-year math: packs/day × years smoked

ASCVD risk thresholds:

Grade D / "do not" list (commonly tested distractors):

Preeclampsia high-risk → aspirin 81 mg after 12 weeks: prior preeclampsia, chronic HTN, DM, renal disease, autoimmune, multifetal

Folic acid dose: 0.4–0.8 mg daily preconception

HPV vaccine: through 26, shared decision 27–45 (ACIP/USPSTF aligned)

Board Question Stem Patterns

— "A 49-year-old asymptomatic woman... what is the most appropriate screening?" → Answer: colonoscopy or FIT (Grade B at 45–49) AND mammography (Grade B at 40–74). Pick whichever is not yet done in the stem

— "A 39-year-old asks about mammography" → not yet recommended; address risk factors

— Stem offers an attractive but wrong option: vitamin D for falls, aspirin in a 65-year-old, carotid duplex in an asymptomatic patient, CA-125, PSA in a 75-year-old

— Recognize Grade D and pick a Grade A/B alternative

— Positive FIT → colonoscopy, not repeat FIT

— Reactive HCV antibody → HCV RNA

— Initial BP 152/94 in clinic → ambulatory or home BP monitoring (confirm before diagnosing)

— PHQ-9 of 15 → initiate treatment (SSRI ± therapy), not "repeat in 2 weeks"

— High-risk for preeclampsia at 14 weeks → aspirin 81 mg

— First prenatal visit labs: HIV, HBV, syphilis, Rh, urine culture timing

— Planning pregnancy → folic acid 0.4–0.8 mg

— Calculate pack-years; if ≥20 and quit <15 yrs → annual low-dose CT

— If male 65–75 ever smoked → one-time AAA US

— PSA 55–69 → shared decision-making discussion, not automatic PSA

— Aspirin 40–59 → discuss benefits/harms

— 82-year-old healthy woman with normal prior mammograms → stop mammography (Grade I ≥75)

— 70-year-old asking about PSA → do not screen (Grade D)

Board pearl: The single most testable concept across all 20 chunks: match the patient's age, risk factor, and last-screening date to the current USPSTF grade. If you can recite the age cutoffs and the Grade D "do not" list, you will get the majority of prevention questions correct.

Pattern 1 — The age threshold trap:

Pattern 2 — The Grade D distractor:

Pattern 3 — Positive screen → next step:

Pattern 4 — Pregnant patient prevention:

Pattern 5 — Smoker over 50:

Pattern 6 — Counseling vs testing:

Pattern 7 — Stop screening:

One-Line Recap

USPSTF Grade A and B recommendations define the evidence-based core of adult preventive care — Step 3 rewards you for matching the right screening test, chemoprevention, or counseling intervention to the right patient at the right age while avoiding Grade D services and shared-decision-making pitfalls.

Board pearl: When a Step 3 vignette describes an asymptomatic adult presenting for routine care, build your differential of preventive interventions the way you'd build a clinical differential — list the eligible A/B services by age and risk factor, exclude what's already been done, exclude Grade D distractors, and select the highest-evidence, not-yet-completed intervention. That single algorithm captures the majority of USPSTF questions on the exam.

Top-yield numbers: Cervical 21–65, Breast 40–74, Colorectal 45–75, Lung 50–80 (20 pack-years, quit <15y), AAA 65–75 male smokers (once), Diabetes 35–70 if overweight, HIV 15–65 (once), HCV 18–79 (once), Statin 40–75 (≥1 RF + ASCVD ≥10%), Osteoporosis women ≥65

Top "do NOT do" pearls: aspirin primary prevention ≥60, vitamin D for falls, screening pelvic in asymptomatic women, asymptomatic carotid duplex, ovarian/thyroid/pancreatic cancer screening, beta-carotene/vitamin E, postmenopausal hormones for chronic disease prevention

Top shared-decision-making slots: PSA 55–69, aspirin 40–59 with ASCVD ≥10%, lung LDCT in eligible smokers, BRCA testing referral

Top pregnancy actions: folic acid 0.4–0.8 mg preconception, aspirin 81 mg after 12 weeks if high preeclampsia risk, first-visit HIV/HBV/syphilis/Rh, urine culture 12–16 weeks, GDM at 24 weeks, depression screen with treatment systems in place